ENHANCING VACCINE-ELICITED PROTECTIVE IMMUNITY IN MALARIA Release Date: February 19, 1999 RFA: AI-99-006 P.T. National Institute of Allergy and Infectious Diseases Letter of Intent Receipt Date: March 22, 1999 Application Receipt Date: May 20, 1999 THIS RFA USES THE "MODULAR GRANT" AND "JUST-IN-TIME" CONCEPTS. IT INCLUDES DETAILED MODIFICATIONS TO STANDARD APPLICATION INSTRUCTIONS THAT MUST BE USED WHEN PREPARING APPLICATIONS IN RESPONSE TO THIS RFA. PURPOSE The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) invites applications for research project (R01) grants to conduct innovative research to advance fundamental understanding of eliciting optimal protective immune responses with candidate malaria vaccines. As part of its Malaria Vaccine Development Plan, NIAID seeks to identify and validate methods and strategies for improved antigen delivery, processing, and presentation or enhancement of protective immunity with existing candidate antigens. Identification, characterization and evaluation of new candidate vaccines, especially combination vaccines based on a rational strategy for antigen inclusion, are also encouraged. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This RFA, Enhancing Vaccine-Elicited Protective Immunity in Malaria, is related to the priority area(s) of immunization and infectious diseases. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0 or Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-512-1800). ELIGIBILITY REQUIREMENTS Applications may be submitted by domestic and foreign for-profit and non-profit organizations; public and private institutions, such as universities, colleges, hospitals, laboratories, units of State and local governments; and eligible agencies of the Federal government. Racial/ethnic minority individuals, women, and persons with disabilities are encouraged to apply as Principal Investigators. MECHANISM OF SUPPORT The mechanism of support will be the individual research project grant (R01). The total requested project period for an application submitted in response to this RFA may not exceed five years. However, specific application instructions have been modified to reflect "MODULAR GRANT" and "JUST-IN-TIME" streamlining efforts being examined by the NIH. The modular grant concept establishes specific modules in which direct costs may be requested as well as a maximum level for requested budgets. Only limited budgetary information is required under this approach. The just-in-time concept allows applicants to submit certain information only when there is a possibility for an award. It is anticipated that these changes will reduce the administrative burden for the applicants, reviewers and Institute staff. Complete and detailed instructions and information on Modular Grants can be found at https://grants.nih.gov/grants/funding/modular/modular.htm. Applications will request direct costs in $25,000 modules, up to a total direct cost request of $250,000 per year. A typical modular grant application will request the same number of modules in each year. Application budgets will be simplified. Detailed categorical budget information will not be submitted with the application; budget form pages of the application kits will not be used. Instead, total direct costs requested for each year will be presented. Information, in narrative form, will be provided only for Personnel and, when applicable, for Consortium/Contractual Costs. See section on APPLICATION PROCEDURES below. Additional narrative budget justification will be required in the application only if there is a variation in the number of modules requested. There will be no routine escalation for future years. In determining the total for each budget year, applicants should first consider the direct cost of the entire project period. Well-justified modular increments or decrements in the total direct costs for any year of the project that reflect substantial changes in expected future activities may be requested. For example, purchase of major equipment in the first year may justify a higher overall budget in the first, but not in succeeding years. Other Support pages of the PHS 398 will not be submitted with the application. Information on research projects ongoing or completed during the last three years of the principal investigator and key personnel will be provided as part of the "Biographical Sketch." This information will include the specific aims, overall goals and responsibilities and should include Federal and non-Federal support. This information will be used by reviewers in the assessment of each individuals qualifications for a specific role in the proposed project. Following peer review, information about Other Research Support will be requested by NIH from the applicant for applications being considered for award. Additional budget information will be requested only under special circumstances. This RFA is a one-time solicitation. Future unsolicited competing continuation applications will compete with all investigator-initiated applications and be reviewed according to the customary peer review procedures. Responsibility for the planning, direction, and execution of the proposed project will be solely that of the applicant. FUNDS AVAILABLE It is anticipated that for fiscal year 2000, approximately $1 millions total costs will be available for the first year of support for this initiative. Award of grants pursuant to this RFA is contingent upon receipt of such funds for this purpose. It is anticipated that up to 4 new grants will be awarded under this program. Applicants may request up to 5 years of support. Direct costs will be awarded in modules of $25,000, less any overlap or other necessary administrative adjustments. Facilities and Administrative costs will be awarded based on the negotiated rates. The usual PHS policies governing grants administration and management will apply. Although this program is provided for in the financial plans of the NIAID, awards pursuant to this RFA are contingent upon the availability of funds for this purpose and the receipt of a sufficient number of applications of high scientific merit. Funding beyond the first and subsequent years of the grant will be contingent upon satisfactory progress during the preceding years and availability of funds. RESEARCH OBJECTIVES Background Malaria continues to impose a tremendous health burden for people living in the tropics, particularly in Africa. It is estimated that half a billion people worldwide are infected with malaria, and between 1.5 and 2.7 million people die of this disease each year. The situation is worsening, as drug resistant strains of the most virulent form of malaria parasite, Plasmodium falciparum, have spread to most endemic regions. At-risk groups include those in whom immunity has not yet developed (young children in endemic areas, travelers, etc.) and those in whom immunity has waned (pregnant women, the elderly and people from endemic areas who have ceased to be routinely exposed to infection). Since many of the poorest nations of the world are afflicted with malaria, to be effective any intervention must be inexpensive, cost-effective, and relatively easy to administer and maintain. Historically, vaccines have been among the most cost-effective and easily administered means of controlling infectious diseases, but as yet no licensed vaccines exist for malaria. Nevertheless, there are reasons to believe that protective immunity against malaria can be elicited. Human populations residing in malaria endemic areas have been observed to acquire immunity to clinical disease naturally over time. Experimental vaccination with attenuated malaria parasites has also been shown to result in effective immune protection against challenge with malaria parasites. Vaccines based on live, attenuated or killed malaria parasites are economically and technically impracticable; much of the current research, therefore, focuses on recombinant or synthetic subunit vaccines. The aforementioned observations and accumulating basic and clinical research suggest that vaccines for malaria can be developed that could significantly reduce morbidity and mortality as well as potentially reduce the spread of infection. A subunit vaccine against P. falciparum pre-erythrocytic stages has recently demonstrated protective efficacy in a small clinical trial involving experimental challenge of previously vaccinated volunteers (Stoute et al., N. Engl. J. Med. 1997; 336:86-91), and a small trial of this vaccine is now ongoing in a malaria endemic region. An optimal vaccine would have the ability to elicit protective immunity that not only blocks infection, but also prevents pathology and inhibits transmission of parasites. This would most likely require a combination vaccine comprising subunits from different parasite stages. Compared to vaccines for most acute bacterial or viral diseases, development of malaria vaccines presents formidable obstacles in terms of parasite biology, host immune responses, and both preclinical and clinical evaluation. Four different species of protozoan parasites cause human malaria; because of its severity, however, most vaccine efforts have been directed to falciparum malaria. Furthermore, even parasite isolates of the same species but from different geographic locations may be immunologically distinct. Finally, malaria parasites have complex life cycles, and, thus, distinct developmental stages, each of which may have multiple antigens that could serve as targets of an immune response. Host immunity to malaria is likewise complex. Naturally occurring immunity is slow to develop and wanes rapidly. Multiple different immune responses, both humoral and cellular, appear capable of contributing to protective immunity, although to date, no immune response predictive of protection in humans has been clearly identified or validated. In 1997, NIAID developed a Research Plan for Malaria Vaccine Development (http://www.niaid.nih.gov/Dmid/malvacdv/toc.htm). This Plan aims to accelerate research leading to the development of a vaccine to reduce mortality and morbidity resulting from malaria. The NIAID Plan provides for: o Improved access to well characterized research materials o Increased discovery and preclinical testing of new vaccine candidates o Enhanced capacity for production and evaluation of candidate malaria vaccines o Establishment of clinical research and trial preparation sites in endemic areas Over the past two years, NIAID has sought to implement this plan systematically through solicitations for expanded clinical research, creation of a malaria reagent repository, and expansion of facilities for vaccine production and evaluation. This RFA addresses another important component of the NIAID plan, involving research on characterization of candidate vaccine antigens and identification and validation of superior strategies and technologies for vaccination. Recent advances in immunology, as well as molecular and cellular biology, have led to an improved understanding of potential mechanisms of protective immunity and of the biology of the malaria parasite. New insights into the role of antigen processing and presentation in the development of immune responses, along with a more comprehensive appreciation of the immunoregulatory effects of cytokines, need to be studied in relation to enhancing vaccine- elicited protective immunity, especially for currently identified vaccine candidates. Furthermore, the information expected to come from genetic sequencing projects will likely reveal a wealth of new antigens for future studies. Focused efforts are necessary to determine whether these fundamental discoveries can be targeted to the development of new prevention or intervention strategies. This initiative should be considered as a component of the overall NIAID Research Plan for Malaria Vaccine Development, with an opportunity for promising research to be expanded and pursued collaboratively in the context of other Institute- supported programs. Research Objectives and Scope NIAID seeks to foster innovative research to develop methods for improved antigen delivery/presentation or enhancement of protective immunity with existing candidate vaccine antigens, as well as to identify and characterize new candidate vaccines. It is anticipated that the bulk of this research will be pursued at the preclinical level, and will involve the use of appropriate animal models of malaria. Investigators anticipating studies involving human subjects should contact the Program Officer (see "INQUIRIES" below) for additional guidance. Relevant research includes, but is not limited to, the following: o Identification and validation of antigens as promising candidate vaccines to prevent infection, disease and/or transmission o Evaluation, in animal models, of vaccines based on combinations of antigens o Identification, validation and optimization of appropriate formulations (e.g. delivery systems, adjuvants) of candidate vaccines that can elicit long-lasting protective immunity in animal models o Characterization and quantitative assessment of specific effector mechanisms of protective immunity operating in these models o Identification and evaluation of innovative strategies and mechanisms to sustain protective effector mechanisms and/or boost waning responses o Development of in vitro assays that could serve as correlates of vaccine efficacy for future clinical trials The areas outlined above are not intended to be all-inclusive. SPECIAL REQUIREMENTS Principal Investigators should budget for a trip to attend an annual, three day meeting sponsored by NIAID in the Washington DC area. These meetings will allow investigators to meet with other participants capable of providing access to relevant information, technologies and/or patient populations. It is expected that such meetings will foster collaboration between basic and clinical researchers, and expedite clinical applications of research findings where appropriate. INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS It is the policy of the NIH that women and members of minority groups and their sub-populations must be included in all NIH supported biomedical and behavioral research projects involving human subjects, unless a clear, compelling rationale, and justification are provided that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research. This policy results from the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43). All investigators proposing research involving human subjects should read the "NIH Guidelines for Inclusion of Women and Minorities as Subjects in Clinical Research", published in the Federal Register of March 28, 1994 (FR 59 14508- 14513) and the NIH Guide for Grants and Contracts, Vol. 23, No. 11, March 18, 1994 which is available via the WWW. at: https://grants.nih.gov/grants/guide/notice-files/not94-100.html INCLUSION OF CHILDREN AS PARTICIPANTS IN RESEARCH INVOLVING HUMAN SUBJECTS It is the policy of NIH that children (i.e., individuals under the age of 21) must be included in all human subjects research, conducted or supported by the NIH, unless there are scientific and ethical reasons not to include them. This policy applies to all initial (Type 1) applications submitted for receipt dates after October 1, 1998. All investigators proposing research involving human subjects should read the "NIH Policy and Guidelines on the Inclusion of Children as Participants in Research Involving Human Subjects" that was published in the NIH Guide for Grants and Contracts, March 6, 1998, and which is available at the following URL address: https://grants.nih.gov/grants/guide/notice-files/not98-024.html Investigators may obtain copies from these sources or from Dr. B.F. Hall(listed in INQUIRIES below) who may also provide additional relevant information concerning the policy. LETTER OF INTENT Prospective applicants are asked to submit, by March 22, 1999, a letter of intent that includes a descriptive title of the overall proposed research; the name, address and telephone number of the Principal Investigator; and the number and title of this RFA. Although the letter of intent is not required, is not binding, does not commit the sender to submit an application, and does not enter into the review of subsequent applications, the information that it contains allows NIAID staff to estimate the potential review workload and to avoid conflict of interest in the review. The letter of intent is to be sent to Dr. B.F. Hall at the address listed under INQUIRIES. APPLICATION PROCEDURES Applicants are strongly encouraged to contact NIAID program staff listed under INQUIRIES with any questions regarding the responsiveness of their proposed project to the goals of this RFA. The research grant application form PHS 398 (rev. 4/98) is to be used in applying for these grants. Application kits are available at most institutional offices of sponsored research and from the Division of Extramural Outreach and Information Resources, National Institutes of Health, 6701 Rockledge Drive, MSC 7910, Bethesda, MD 20892-7910, telephone (301) 710-0267, email:GrantsInfo@nih.gov. Applications are also available on the World Wide Web at: https://grants.nih.gov/grants/forms.htm. BUDGET INSTRUCTIONS The total direct costs must be requested in accordance with the program guidelines and the modifications made to the standard PHS 398 application instructions described below: o FACE PAGE: Items 7a and 7b should be completed, indicating Direct Costs (in $25,000 increments up to a maximum of $250,000) and Total Costs [Modular Total Direct plus Facilities and Administrative (F&A) costs] for the initial budget period. Items 8a and 8b should be completed indicating the Direct and Total Costs for the entire proposed period of support. o DETAILED BUDGET FOR THE INITIAL BUDGET PERIOD - Do not complete Form Page 4 of the PHS 398. It is not required and will not be accepted with the application. o BUDGET FOR THE ENTIRE PROPOSED PERIOD OF SUPPORT - Do not complete the categorical budget table on Form Page 5 of the PHS 398. It is not required and will not be accepted with the application. o NARRATIVE BUDGET JUSTIFICATION - Use a Modular Grant Budget Narrative page. (See https://grants.nih.gov/grants/funding/modular/modular.htm for sample pages.) At the top of the page, enter the total direct costs requested for each year. o Under Personnel, List key project personnel, including their names, percent of effort, and roles on the project. No individual salary information should be provided. For Consortium/Contractual costs, provide an estimate of total costs (direct plus facilities and administrative) for each year, each rounded to the nearest $1,000. List the individuals/organizations with whom consortium or contractual arrangements have been made, the percent effort of key personnel, and the role on the project. Indicate whether the collaborating institution is foreign or domestic. The total cost for a consortium/ contractual arrangement is included in the overall requested modular direct cost amount. Provide an additional narrative budget justification for any variation in the number of modules requested. o BIOGRAPHICAL SKETCH - The Biographical Sketch provides information used by reviewers in the assessment of each individual's qualifications for a specific role in the proposed project, as well as to evaluate the overall qualifications of the research team. A biographical sketch is required for all key personnel, following the instructions below. No more than three pages may be used for each person. A sample biographical sketch may be viewed at: https://grants.nih.gov/grants/funding/modular/modular.htm - Complete the educational block at the top of the form page; - List current position(s) and then previous positions; - List selected peer-reviewed publications, with full citations; - Provide information, including overall goals and responsibilities, on research projects ongoing or completed during the last three years. o CHECKLIST - This page should be completed and submitted with the application. If the F&A rate agreement has been established, indicate the type of agreement and the date. It is important to identify all exclusions that were used in the calculation of the F&A costs for the initial budget period and all future budget years. o The applicant should provide the name and phone number of the individual to contact concerning fiscal and administrative issues if additional information is necessary following the initial review. Applicants not conforming to these guidelines will be considered unresponsive to this RFA and will be returned without further review. The RFA label available in the application form PHS 398 must be affixed to the bottom of the face page. Failure to use this label could result in delayed processing of the application such that it may not reach the review committee in time for review. For purposes of identification and processing, item 2 on the face page of the application must be marked "YES" and the RFA number "AI-99-006" and the words "Enhancing Vaccine-Elicited Protective Immunity in Malaria" must be entered on the face page. Submit a signed, typewritten original of the application, including the checklist, and five signed, exact, single-sided photocopies, in one package to: CENTER FOR SCIENTIFIC REVIEW NATIONAL INSTITUTES OF HEALTH 6701 ROCKLEDGE DRIVE, ROOM 1040 - MSC 7710 BETHESDA, MD 20892-7710 BETHESDA, MD 20817 (for express/courier service) Applicants from institutions that have a General Clinical Research Center (GCRC) funded by the NIH National Center for Research Resources may wish to identify the GCRC as a resource for conducting the proposed research. If so, a letter of agreement from either the GCRC Program Director or Principal Investigator should be included with the application. Applications must be received by May 20, 1999. Applications not received as a single package on the receipt date or not conforming to the instructions contained in PHS 398 (rev. 4/98) Application Kit (as modified in, and superseded by, the special instructions above, for the purposes of this RFA), will be judged non-responsive and will be returned to the applicant. The Center for Scientific Review (CSR) will not accept any applications in response to this RFA that is essentially the same as one currently pending initial review, unless the applicant withdraws the pending application. The CSR will not accept any application that is essentially the same as one already reviewed. This does not preclude the submission of substantial revisions of applications already reviewed, but such applications must include an introduction addressing the previous critique. REVIEW CONSIDERATIONS Upon receipt, applications will be reviewed for completeness and adherence to the Special Instructions above by CSR and for responsiveness by NIAID staff. Incomplete and/or non-responsive applications will be returned to the applicant without review. Applications that are complete and responsive to the RFA will be evaluated for scientific and technical merit by an appropriate peer review group convened by the CSR in accordance with the review criteria stated below. As part of the initial merit review, a process will be used by the initial review group in which applications receive a written critique and under go a process in which only those applications deemed to have the highest scientific merit, generally the top half of the applications under review, will be discussed, assigned a priority score, and receive a second level review by the National Advisory Allergy and Infectious Diseases Council. Review Criteria The goals of NIH-supported research are to advance our understanding of biological systems, improve the control of disease, and enhance health. The reviewers will comment on the following aspects of the application in their written critiques in order to judge the likelihood that the proposed research will have a substantial impact on the pursuit of these goals. Each of these criteria will be addressed and considered by the reviewers in assigning the overall score weighting them as appropriate for each application. Note that the application does not need to be strong in all categories to be judged likely to have a major scientific impact and thus deserve a high priority score. For example, an investigator may propose to carry out important work that by its nature is not innovative but is essential to move a field forward. 1. Significance. Does this study address an important problem? If the aims of the application are achieved, how will scientific knowledge be advanced? What will be the effect of these studies on the concepts or methods that drive this field? 2. Approach. Are the conceptual framework, design, methods, and analyses adequately developed, well-integrated, and appropriate to the aims of the project? Does the applicant acknowledge potential problem areas and consider alternative tactics? 3. Innovation. Does the project employ novel concepts, approaches or method? Are the aims original and innovative? Does the project challenge or advance existing paradigms, or develop new methodologies or technologies? 4. Investigator. Is the investigator appropriately trained and well suited to carry out this work? Is the work proposed appropriate to the experience level of the principal investigator and other researchers (if any)? 5. Environment. Does the scientific environment in which the work will be done contribute to the probability of success? Do the proposed experiments take advantage of unique features of the scientific environment or employ useful collaborative arrangements? Is there evidence of institutional support? The initial review group will also examine the appropriateness of proposed project budget and duration; the adequacy of plans to include both genders, minorities and their subgroups, and children as appropriate for the scientific goals of the research and plans for the recruitment and retention of subjects; the provisions for the protection of human and animal subjects; and the safety of the research environment. The personnel category will be reviewed for appropriate staffing based on the requested percent effort. The direct costs budget request will be reviewed for consistency with the proposed methods and specific aims. Any budgetary adjustments recommended by the reviewers will be in $25,000 modules. The duration of support will be reviewed to determine if it is appropriate to ensure successful completion of the requested scope of the project. AWARD CRITERIA Funding decisions will be made on the basis of scientific and technical merit as determined by peer review, program balance, and the availability of funds. The earliest anticipated date of award is April 1, 2000. INQUIRIES Inquiries concerning this RFA are encouraged. The opportunity to clarify any issues or questions from potential applicants is welcome. Direct inquiries regarding programmatic issues to: Dr. B.F. Hall Division of Microbiology and Infectious Diseases National Institute of Allergy and Infectious Diseases 6003 Executive Boulevard, Room 3A09 Bethesda, MD 20892-7630 Telephone: (301) 496-2544 FAX: (301) 402-0659 Email: bh24q@nih.gov Direct inquiries regarding fiscal matters to: Maryellen Connell Division of Extramural Activities National Institute of Allergy and Infectious Diseases 6003 Executive Boulevard, Room 4B27 Bethesda, MD 20892 Telephone: (301) 402-5576 Fax: (301) 480-3780 Email: mc40u@nih.gov Schedule Letter of Intent Receipt Date: March 22, 1999 Application Receipt Date: May 20, 1999 Scientific Review Date: October 1999 Advisory Council Date: February 2000 Earliest Award Date: April 2000 AUTHORITY AND REGULATIONS This program is described in the Catalog of Federal Domestic Assistance Nos. 93.856 and 93.855. Awards are made under authorization of the Public Health Service Act, Sec. 301 (c), Public Law 78-410, as amended. The awards will be administered under PHS grants policies and Federal Regulations 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems review. The Public Health Service strongly encourages all grant and contract recipients to provide a smoke-free workplace and promote the non-use of all tobacco products. In addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities (or, in some cases, any portion of a facility) in which regular or routine education, library, day care, health care or early childhood development services are provided to children. This is consistent with the PHS mission to protect and advance the physical and mental health of the American people.
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files. |